Molecular Subtypes of Breast Cancer

Luminal A, Luminal B, HER2 and Basal types—and how they differ from routine pathology labels

Key takeaways

• Receptor status, molecular subtype, grade and stage describe different aspects of breast cancer.
• Luminal A and Luminal B labels depend on the classification method being used.
• BluePrint reports Luminal-type, HER2-type or Basal-type; MammaPrint risk further stratifies Luminal tumors in the combined framework.^[2]
• HER2-type is not automatically the same as HER2-positive by standard pathology.
• A subtype result should be interpreted with the complete diagnostic and clinical picture.

Why breast cancer has several kinds of labels

Breast-cancer subtype describes aspects of tumor biology, but not every subtype label comes from the same test. Understanding the difference between receptor testing, gene-expression profiling and stage helps make reports easier to discuss.

A breast-cancer report may describe the tumor's histological type, grade, receptor findings and stage. Additional genomic tests can add information about gene-expression patterns or recurrence risk. These labels are not redundant: each describes a different part of the disease.^[1]

This can make the report feel contradictory when it is not. For example, a stage number does not explain which growth pathways are active, and a receptor result does not tell you the full extent of the disease. When a new label appears, first ask what was measured and which question that test was intended to answer.

Oncquest's cancer-testing portfolio spans molecular diagnostics as well as surgical pathology and IHC. Its MammaPrint plus BluePrint combination adds gene-expression information to that wider diagnostic context. Knowing which Oncquest investigation produced each result helps you keep receptor findings, recurrence risk and molecular subtype distinct.^[7][5]

Label or assessment	Important distinction
Luminal A / Luminal B	Biological group labels; the method used to assign them matters.
BluePrint Luminal-type	Can be combined with MammaPrint risk to derive A-type or B-type.
HER2-positive by pathology	Not automatically identical to a gene-expression HER2-type label.
Triple-negative by pathology	Defined by ER, PR and HER2 results; overlaps with but is not identical to Basal-type.
Stage / grade	Stage concerns disease extent; grade concerns microscopic appearance. Neither is a molecular subtype.

What routine ER, PR and HER2 testing assesses

Estrogen receptor (ER) and progesterone receptor (PR) testing help identify hormone-receptor status. HER2 assessment examines the relevant protein expression and, when indicated, gene amplification using the appropriate pathology methods. These results have established roles in breast-cancer classification and treatment planning.^[1]

Routine pathology may use the terms hormone-receptor positive, HER2-positive or triple-negative. These are clinically important descriptions, but they should not be assumed to be identical to every gene-expression subtype. Keep the actual percentages, scores and final interpretation from the pathology report available; a shortened label may omit information the oncologist needs.

What molecular subtyping adds

Gene-expression profiling examines patterns of gene activity in tumor tissue. Rather than checking only an individual receptor, it evaluates a signature intended to characterise aspects of the tumor's biology. The output depends on the specific assay and classification framework.

BluePrint is an 80-gene expression test that assigns a functional Luminal-type, HER2-type or Basal-type classification. Its manufacturer sample report describes correlation scores for those patterns and a reported subtype. These are not percentages of tumor cells, and a person should not interpret several displayed scores as proof of having several separate cancers.^[3]

Understanding Luminal A and Luminal B

Luminal labels describe biological groups often associated with hormone-related pathways. However, reports can use an expression-based classification or a clinicopathological approximation. A term such as luminal-like may therefore not mean exactly the same thing as a result from a specific genomic assay.

Within the MammaPrint plus BluePrint framework, a BluePrint Luminal-type tumor is further grouped using the MammaPrint risk result: Low Risk corresponds to Luminal A-type and High Risk to Luminal B-type. Do not transfer this rule to an unrelated test system or derive it from ER positivity alone. It is a mapping within the named combined framework.^[3]

Why HER2-type and HER2-positive are different

A molecular HER2-type result describes a gene-expression pattern associated with that functional pathway. A standard HER2-positive pathology result is assigned using established laboratory scoring and interpretation of HER2 testing. The two approaches measure different features and may not always align.^[2]

If a report uses both terms, retain both results in the medical record and ask the team to explain them. Do not decide that a genomic label automatically creates or removes eligibility for a HER2-directed treatment. The appropriate pathology results, current treatment criteria and the person's clinical situation need to be assessed together.

Basal-type is not a synonym for triple-negative

Triple-negative breast cancer is defined by the absence of ER and PR positivity and a HER2-negative result under the applicable pathology criteria. Basal-type is a molecular classification. There is overlap between these groups, but the labels should not be treated as interchangeable.^[1][2]

A result that appears unexpected deserves a careful review of the specimen, assay and complete pathology findings. It is not a reason to abandon an existing treatment plan independently. Ask whether the distinction adds clinically useful information, whether any confirmation is needed and which established findings are being used for the treatment decision.

Subtype does not tell you stage or inherited risk

Stage describes the extent of cancer using the relevant clinical and pathological information. Grade concerns how the cells look under the microscope. A molecular subtype or genomic risk category cannot, on its own, determine either one. A label containing the word high is not equivalent to advanced-stage disease.^[1]

Likewise, tumor gene-expression testing is not a test of inherited cancer susceptibility. A Basal or Luminal result alone does not establish that relatives carry a pathogenic variant. Personal and family history may justify a separate inherited-risk discussion, but that assessment has its own consent, testing and counselling process.^[6]

Where the Oncquest combination fits

Verified Oncquest offering facts

1

Method and specimen

Oncquest offers MammaPrint plus BluePrint as test SMO10242, a microarray-based gene-expression profile using FFPE tumor material.

Why it matters for you

MammaPrint contributes recurrence-risk information, while BluePrint contributes functional subtype information. This is a defined breast-cancer offering, not a comprehensive search for all breast-cancer mutations or a substitute for ER, PR and HER2 pathology.

2

Listed tissue requirements

Its catalogue specifies an FFPE block or 10 unstained slides with a 5-micron section on each slide and at least 30% invasive tumor.

Why it matters for you

If the oncologist recommends this combination, ask Oncquest to confirm the specimen instructions before tissue is prepared. The pathology team should assess suitability. The oncologist determines whether the additional genomic information is useful in the patient's setting.

Making sense of a mixed set of results

• Write down the exact subtype label and the test that produced it.
• Keep the ER, PR and HER2 pathology results beside the genomic report.
• Ask whether Luminal A or B was directly reported or inferred from another framework.
• Separate recurrence-risk information from subtype, stage and grade.
• Ask the treating team to explain any apparent disagreement between methods.
• Confirm which findings change the care discussion and which add context only.

For an Oncquest test enquiry, call 0124 6650000 or email life@oncquestlabs.com and name the MammaPrint plus BluePrint combination, SMO10242. Confirm the requested report outputs and specimen arrangements. At the results appointment, keep the subtype and its method beside the receptor findings, then ask the oncologist to explain how each result affects the care discussion.^[8][5]

Frequently asked questions

FAQs

Are Luminal A and Luminal B stages of breast cancer?

No. They are biological group labels. Stage describes the extent of disease and is determined separately.

Does BluePrint directly report four subtypes?

BluePrint’s functional groups are Luminal-type, HER2-type and Basal-type. In the combined framework, MammaPrint risk further distinguishes Luminal A-type from Luminal B-type.

Does ER-positive always mean Luminal A?

No. ER is one pathology marker. Luminal A or B depends on the classification framework and additional information; ER positivity alone does not assign either label.

Is HER2-type the same as HER2-positive?

Not automatically. A gene-expression subtype and routine HER2 pathology assess different features. Both require interpretation in the clinical context.

Are all triple-negative tumors Basal-type?

The groups overlap but are not identical. Triple-negative is a receptor-based description; Basal-type is a molecular classification.

Can a molecular subtype replace the pathology report?

No. The full pathology findings, stage, clinical history and any genomic results are interpreted together. A subtype label should not independently determine treatment.

Sources

1. National Cancer Institute — Breast Cancer Types Context on breast-cancer classifications and biomarkers.
2. Agendia — BluePrint Manufacturer context on the 80-gene functional subtypes.
3. Agendia — BluePrint Luminal Example Report Published example explaining subtype scores and the combined Luminal A/B framework.
4. Agendia — MammaPrint Manufacturer context on the 70-gene signature and clinical interpretation.
5. Oncquest — MammaPrint + BluePrint Combination Official combination offering, method and sample requirements.
6. National Cancer Institute — Genetic Testing Fact Sheet Inherited-risk testing, consent and genetic counselling.
7. Oncquest — Company Overview Oncology focus, specialised diagnostic disciplines and laboratory network.
8. Oncquest — Patient Services and Enquiries Test search, centre search, online report access and published enquiry contacts.